Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Cabilly Saga: New Patent, New Product, New Lawsuits

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech seeks Benlysta royalties from HGS and GSK through enforcement of the Cabilly III patent.

You may also be interested in...



Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics

Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.

HGS Anticipates Broad SLE Patient Access For Benlysta

With launch just underway of its newly approved lupus drug, HGS is seeing encouraging signs early on from payers.

HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions

The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel